Neurotech International (ASX:NTI) - Executive Director, Dr Thomas Duthy
Executive Director, Dr Thomas Duthy
Source: Thomas Duthy/LinkedIn
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Neurotech International (NTI) treats its first patient in its phase one and two paediatric clinical trials
  • The trials are assessing the company’s NTI164 product in children with paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and paediatric acute-onset neuropsychiatric syndrome (PANS)
  • Neurotech Executive Director Thomas Duthy said the milestone signalled the interest the company’s leading treatment had generated
  • The company says the recruitment of the 15 patients will be completed during the first quarter of 2023, with results anticipated in H2 2023
  • Shares in NTI are down 3.64 per cent, trading at 5.3 cents at 3:00 pm AEDT

Neurotech International (NTI) has treated its first patient in its phase one and two paediatric clinical trials.

The trials are assessing Neurotech’s NTI164 treatment in children diagnosed with paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and paediatric acute-onset neuropsychiatric syndrome (PANS).

Neurotech Executive Director Thomas Duthy said the milestone signalled the interest the company’s leading treatment had generated.

“It is a testament to the interest this novel clinical trial has generated that the first patient of our planned 15 patients has received treatment so soon after receiving human ethics approval,” Dr Duthy said.

Neurotech received approval from the Human Research Ethics Committee (HREC) to begin its trials back on January 27, 2023.

NTI164 is Neurotech’s leading treatment aiming to improve the quality of life for children suffering from paediatric disorders.

The company said it expected the recruitment of the 15 patients to be completed during the first quarter of 2023, with results anticipated for the second half of 2023.

The trials remain open to enrolment at two centres in Australia — the Children’s Hospital at Westmead in New South Wales and the Paediatric Neurology Unit at Monash Medical Centre in Victoria.

Shares in NTI were down 3.64 per cent and trading at 5.3 cents at 3:00 pm AEDT.

NTI by the numbers
More From The Market Online
The Market Online Video

ASX Market Update: Bourse surrenders gains | 19 July 2024

The ASX is down 1% as the market falls back below 8000 points after record highs…
The Market Online Video

ASX Market Close: Index finishes the week lower | 19 July 2024

In market close this afternoon we are discussing Droneshield, Universal Store Holdings, Flynn Gold, Lifestyle Communities,…